Randall T. Peterson, MD
Associate Professor of Medicine
Harvard Medical School
Assistant in Biology
Massachusetts General Hospital
Research SummaryThe Peterson laboratory focuses on discovering bioactive small molecules by high-throughput in vivo screening. Whereas chemical screening has traditionally focused on simple, in vitro assays, many biological phenomena are difficult to reduce to an in vitro assay. The Peterson lab is using the tools of chemical biology to investigate these complex in vivo phenomena. By conducting high-throughput screens with intact, living zebrafish, we can discover small molecules that alter virtually any biological process. The lab is applying this approach in three areas: 1) developmental biology, including cardiovascular development and germ cell development; 2) disease physiology, including heart failure, anemia and leukemia; and 3) animal behaviors. In each of these areas, the novel small molecules discovered are providing new biological insights and/or novel therapeutic opportunities.
Randall T. Peterson, MD
Small molecules are powerful tools for studying developmental biology because they provide timing and dosage control over developmental pathways that is difficult to achieve with genetic mutations. Unfortunately, only a handful of developmental pathways can currently be targeted with small molecules. We are discovering novel chemical modifiers of developmental pathways by exposing zebrafish embryos to libraries of structurally diverse small molecules and identifying those that induce specific developmental defects. Using screens of this type, we have discovered dozens of compounds that cause specific defects in hematopoiesis, embryonic patterning, pigmentation, and morphogenesis of the heart, brain, ear and eye and germ cell lineage.
One notable lab success in recent years has been the discovery of dorsomorphin and related BMP receptor antagonists. These small molecules were discovered during a zebrafish screen for compounds that alter development of the embryonic dorsal-ventral axis. As the first compounds to antagonize BMP signaling, the molecules have become powerful tools for studying BMP functions, and the molecules have already been used in hundreds of other studies around the world. In addition, the compounds have proven to be effective in treating animal models of BMP-related disorders, including heterotopic ossification and anemia. The compounds are currently in late stages of preclinical development.
One focus of our group is modeling human diseases in zebrafish. We use these models to screen large chemical libraries for small-molecule modulators of the disease-related phenotypes. The compounds we discover help us elucidate disease mechanisms and serve as starting points for developing new drug candidates. Disease physiology is often complex and involves interactions between multiple organs and tissue types. Consequently, many diseases cannot be studied effectively using in vitro assays. The zebrafish is an excellent vertebrate model system to study many complex, non-cell autonomous diseases because the diseases can be studied in a native, whole-organism setting. In addition, compounds discovered in zebrafish screens have the advantage of having been selected for their ability to be active, efficacious and well tolerated in animals.
One notable example from the lab was discovery of compounds that suppress the effects of the AML1-ETO oncogene in acute myeloid leukemia (AML). We generated a model of AML by expressing the human AML1-ETO oncogene in zebrafish. These zebrafish accumulate granulocytic blast cells that resemble those found in humans with AML. In a robotic expression screen of thousands of small molecules, we discovered that nimesulide can reverse the oncogenic effects of AML1-ETO, an effect that is conserved in mammalian models of AML.
Behaviors are accessible readouts of the molecular pathways that control neuronal signaling. Our group develops tools and techniques for high-throughput behavioral phenotyping in the zebrafish. These tools have potential to improve our understanding of neuronal signaling and may accelerate the pace of neuroactive drug discovery.
Proto magazine stakes its ground on medicine's leading edge, reporting back from the frontiers of research and practice - exploring breakthroughs, dissecting controversies and opening a forum for informed debate.
Discover the largest hospital-based research program in the U.S. and how clinicians and scientists chart new terrain in biomedical research to treat and prevent human disease and bring the latest advances to patient care